A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Exclusion Criteria

• •Prior Alogenic Bone Marrow Transplant
• •Greater than or equal to (\>/=) 3 previous lines of chemotherapy and/or immunotherapy for the CLL
• •Previous obinutuzumab-containing regimen
• •Treatment failure or progression within 6 months of bendamustine-containing regimen
• •Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL; Richter's transformation) Patients with prolymphocytic transformation cannot entry the study either
• •Active haemolytic anaemia
• •Inadequate liver function
• •History of other malignancy which could affect compliance with the protocol or interpretation of results. Patients with a history of malignancy that has been treated but not with curative intent will be excluded, unless the malignancy has been in remission without treatment for \>/= 2 years prior to enrolment. Patients with a history of adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent are eligible
• •Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
• •Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
• •Regular treatment with corticosteroids during the 4 weeks prior to study start, unless administered for another condition at a dose equivalent to less than or equal to (\</=) 30 milligrams per day (mg/day) prednisone
• •Known active infection or any infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to study start
• •Patients with HIV, human T cell leukemia virus 1 (HTLV-1), hepatitis B or hepatitis C
• •Pregnancy or breast-feeding
• •Vaccination with a live vaccine within 4 weeks prior to baseline visit
• •Receipt of any other study drug within 4 weeks prior to study start